文献速递痛风与晶体性关节病

维立奴拉联合非布司他治疗日本痛风或无症状高尿酸血症成人:一项2a期开放标签研究

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

结果显示联合治疗呈剂量依赖性降低血尿酸,且降幅大于相同剂量非布司他单药(P<0.001),尿尿酸排泄率维持在与基线相当水平,各剂量组合总体耐受良好。

要点

  • 维立奴拉联合非布司他剂量依赖性降低血尿酸,降幅大于同剂量非布司他单药(P<0.001)。
  • 联合治疗时尿尿酸排泄率与基线相当,维立奴拉单药增加排泄,非布司他单药降低排泄。
  • 维立奴拉2.5–15 mg耐受良好,无因不良事件退出,联合治疗实验室指标无临床意义变化。

核心结论

  • 维立奴拉联合非布司他可剂量依赖性降低血尿酸,同时维持尿尿酸排泄与基线相似。
  • 维立奴拉与非布司他所有剂量组合总体耐受良好。
  • 这些数据支持继续研究口服维立奴拉用于痛风患者。

研究设计与样本

  • 2a期、随机、开放标签研究,纳入日本男性21–65岁痛风(n=37)或无症状高尿酸血症(n=35)且血尿酸≥8 mg/dl者。
  • 随机接受非布司他(10、20、40 mg)联合维立奴拉(2.5–10 mg)、维立奴拉单药(2.5–15 mg)、非布司他单药(10、20、40 mg)或苯溴马隆单药(50 mg)。
  • 每队列四个治疗期,每期7天,药物每日早餐后一次给药。

主要发现

  • 维立奴拉联合非布司他剂量依赖性降低血尿酸,相同剂量下降幅大于非布司他单药(P<0.001)。
  • 尿尿酸排泄率:维立奴拉使其增加,非布司他使其降低,联合治疗与基线相当。
  • 维立奴拉2.5–15 mg耐受良好,无因不良事件退出。
  • 联合治疗期间实验室检查无临床意义变化。

关键数值与推荐

  • 血尿酸≥8 mg/dl为入组标准。
  • 维立奴拉联合非布司他降血尿酸优于同剂量非布司他单药(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clinical development for treating gout and asymptomatic hyperuricaemia. The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-dose pharmacodynamics, pharmacokinetics and safety of oral verinurad combined with febuxostat vs febuxostat alone and verinurad alone. METHODS: Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricaemia (n = 35) and serum urate (sUA) ⩾8 mg/dl were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2.5-10 mg), verinurad alone (2.5-15 mg), febuxostat alone (10, 20, 40 mg) or benzbromarone alone (50 mg). There were four treatment periods per cohort and each treatment period was 7 days. Study drugs were administered once-daily after breakfast. Plasma, serum and urine samples were measured at pre-set intervals on days -1, 7, 14, 21 and 28. RESULTS: Verinurad combined with febuxostat decreased sUA in dose-dependent manner, providing greater sUA lowering than febuxostat alone at the same dose (P < 0.001). Urinary uric acid excretion rate was increased by verinurad, reduced by febuxostat and comparable to baseline for verinurad combined with febuxostat. Verinurad from 2.5 mg to 15 mg was well tolerated, with no withdrawals due to adverse events. Laboratory assessments showed no clinically meaningful changes during combination treatment. CONCLUSION: Verinurad combined with febuxostat decreased sUA dose-dependently while maintaining uric acid excretion similar to baseline. All dose combinations of verinurad and febuxostat were generally well tolerated. These data support continued investigation of oral verinurad in patients with gout. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02317861.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Shiramoto M, Liu S, Shen Z, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford). 2018. PMID: 29868853. doi:10.1093/rheumatology/key100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。